Lidia Liu

Bio

Lidia is a Senior Analyst and joined the Public Equity team in 2022. Prior to joining OrbiMed, Lidia was an Analyst at Citadel Global Equities covering biotechnology companies. Previously, she covered biotechnology and specialty pharmaceuticals at EverPoint Asset Management. Before transitioning to the buy side, she was an Associate in the healthcare group at Jefferies. Lidia received a B.S. with high distinction in Physiology from the University of Toronto and a M.S. in Biotechnology from the University of Pennsylvania. Lidia serves on OrbiMed’s culture committee.